(Nexton Bio CI)
Los Vivo Therapeutics announced that it has discovered a miRNA that is effective against the novel coronavirus (COVID-19). The company is currently developing additional new drugs targeting obesity, fatty liver disease, and functional gastrointestinal disorders in addition to diabetes as a metabolic disease pipeline.
According to the company, the anti-coronavirus miRNA discovered by Dr. Roh Seung-il and Rosvivo research team can target all seven types of α (alpha) and β (beta) coronaviruses that infect humans.
Based on the fact that a high mortality rate was observed in patients with a history of diabetes during the course of the COVID-19 pandemic, the Rosvivo research team combined the diabetes RSVI-301 treatment and the anti-coronavirus miRNA COVID-19 treatment discovered by Dr. Noh’s team together. administered to diabetic rats. As a result, the research team confirmed that the hypersensitivity inflammatory response decreased sharply in the experimental group.
Since the first discovery of the COVID-19 virus in 2019, there are a total of five mutant viruses officially recognized by the WHO, from alpha to beta to gamma and the recently discovered micron.
An official from Los Vivo said, “Although the mortality and infection rates for each mutation are different, it is undeniable that the mutation interval is gradually getting shorter in common. We are deploying additional R&D personnel for this,” he said.
Meanwhile, the company is preparing for collaboration with its largest shareholder, Nexton Bio, and domestic bio companies.
.
